Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Growth in Short Interest

Posted by Anthony Miller on Mar 16th, 2025

Windtree Therapeutics, Inc. (NASDAQ:WINT – Get Free Report) saw a significant increase in short interest in February. As of February 28th, there was short interest totalling 83,000 shares, an increase of 44.9% from the February 13th total of 57,300 shares. Based on an average daily volume of 318,400 shares, the days-to-cover ratio is presently 0.3 days. Currently, 11.1% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $350.00 target price on shares of Windtree Therapeutics in a research note on Wednesday, December 4th.

Get Our Latest Analysis on Windtree Therapeutics

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new stake in shares of Windtree Therapeutics, Inc. (NASDAQ:WINT – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned approximately 1.08% of Windtree Therapeutics as of its most recent SEC filing. Institutional investors own 29.33% of the company’s stock.

Windtree Therapeutics Stock Down 0.5 %

Shares of WINT stock opened at $2.05 on Friday. The stock has a 50-day simple moving average of $6.99 and a 200 day simple moving average of $50.92. Windtree Therapeutics has a fifty-two week low of $1.78 and a fifty-two week high of $737.44. The stock has a market capitalization of $1.54 million, a P/E ratio of -0.12 and a beta of 0.68.

Windtree Therapeutics Company Profile

(Get Free Report)

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.